Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials

L Shi, J Tang, L Tong, Z Liu - Lung Cancer, 2014 - Elsevier
Objectives Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC) …
被引用次数：120 相关文章

[引用][C] Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials

L Shi, J Tang, L Tong, Z Liu - Lung Cancer, 2014 - cir.nii.ac.jp
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung
cancer: A systematic review and meta-analysis of clinical trials | CiNii Research CiNii 国立 …

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials

L Shi, J Tang, L Tong, Z Liu - Lung Cancer, 2014 - infona.pl
Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC). Interstitial …

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials.

L Shi, Z Liu, J Tang, L Tong - 2013 - ascopubs.org
e19149 Background: Gefitinib and erlotinib are oral EGFR-TKIs widely used in advanced
NSCLC. The reported incidence and risk of interstitial lung disease (ILD) events associated …

[引用][C] Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials

L SHI, J TANG, LI TONG, ZHE LIU - Lung cancer, 2014 - pascal-francis.inist.fr
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung
cancer: A systematic review and meta-analysis of clinical trials CNRS Inist Pascal-Francis …

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials

L Shi, J Tang, L Tong, Z Liu - Lung cancer (Amsterdam …, 2014 - pubmed.ncbi.nlm.nih.gov
Objectives Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC) …

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials

L Shi, J Tang, L Tong, Z Liu - Lung Cancer, 2014 - lungcancerjournal.info
Objectives Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC) …

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.

L Shi, J Tang, L Tong, Z Liu - Lung Cancer (Amsterdam …, 2013 - europepmc.org
Objectives Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC) …

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials

L Shi, J Tang, L Tong, Z Liu - Lung Cancer, 2014 - infona.pl
Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC). Interstitial …